Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/LSD/Neurocognitive Disorders

LSD for Neurocognitive Disorders

15 papers and 0 clinical trials exploring lsd as a treatment for neurocognitive disorders.

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.

Full LSD profile
IndicationOver 50 million people worldwide suffering from dementia-related disorders.

Neurocognitive Disorders

Neurocognitive disorders, including conditions like dementia and Alzheimer's disease, are characterized by a significant decline in cognitive function. Recent research suggests that psychedelics may offer potential therapeutic benefits by promoting neuronal connectivity and enhancing psychological recovery in these patients.

Full Neurocognitive Disorders profile

Academic Research

15 papers
Open Accessmeta

Side Effects of Microdosing Lysergic Acid Diethylamide and Psilocybin: A Systematic Review of Potential Physiological and Psychiatric Outcomes

This systematic review (s=31) examines the side effects of microdosing LSD and psilocybin, finding that adverse effects are typically dose-dependent, mild, and short-lived. Common side effects include increased blood pressure, anxiety, and cognitive impairment. The review highlights the lack of standardised reporting on side effects and calls for future studies to provide more systematic and transparent assessments.

Published
February 26, 2025
Journal
Neuropharmacology
Authors
Modzelewski, S., Waszkiewicz, N., Lukasiewicz, K., Stankiewisz, A.
Paywallmeta

The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis

This systematic review and meta-analysis (s=6; 2023) assessed the role of psychedelics in treating alcoholism (AUD). LSD and any psychedelic therapy showed enhanced odds of achieving abstinence or reducing alcohol consumption in randomised, double-blind, placebo-controlled trials. However, the study highlights methodological weaknesses in the literature. It suggests that while promising, definitive statements about the value of psychedelics in treating AUD are precluded, emphasizing the need for future trials with greater rigour.

Published
December 18, 2023
Journal
Current Medical Research and Opinion
Authors
Sicignano, D., Hernandez, A. V., Schiff, B., Elmahy, N., White, C. M.
Open Accessindividual

LSD microdosing attenuates the impact of temporal priors in time perception

Pre-registered re-analysis of Yanakieva et al. (2019) shows that LSD microdoses (5–20 μg) reduce the influence of precision-weighted local temporal priors, thereby attenuating the typical under-reproduction bias in time perception. Controlling for those precision-weighted local priors eliminated the LSD effect, indicating the drug acts by downweighting local priors.

Published
April 16, 2023
Journal
Biorxiv
Authors
Sadibolova, R., Murray-Lawson, C., Family, N., Williams, L. T. J., Luke, D. P., Terhune, D. B.
Paywallindividual

LSD and language: Decreased structural connectivity, increased semantic similarity, changed vocabulary in healthy individuals

This double-blind cross-over study (n=24) of a low/moderate dose of LSD (50μg) on the structure of language finds simpler and semantically more similar language after LSD.

Published
March 1, 2023
Journal
European Neuropsychopharmacology
Authors
Wießner, I., Falchi, M., Daldegan-Bueno, D., Palhano-Fontes, F., Olivieri, R., Feilding, A., Araújo, D. B., Ribeiro, S., Mota, N., Tófoli, L.F.
Open Accessmeta

Default Mode Network Modulation by Psychedelics: A Systematic Review

This systematic review shows that classical psychedelics (LSD, psilocybin, ayahuasca) consistently cause acute disruption of resting-state connectivity within the Default Mode Network and increase cross-network functional connectivity, but it remains unclear how central DMN modulation is to their therapeutic effects. The article synthesises existing evidence and highlights gaps to guide future mechanistic research.

Published
October 22, 2022
Journal
International Journal of Neuropsychopharmacology
Authors
Gattuso, J. J., Perkins, D., Ruffell, S. G. D., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L., Pagni, B. A., Galvão-Coelho, N. L., Nutt, D. J., Sarris, J.
Paywallindividual

LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility

This trial (n=24) investigated the effects LSD (50 μg) has on cognition in healthy volunteers. It was found that LSD sub-acutely improved visuospatial memory and phonological verbal fluency and impaired cognitive flexibility when compared to placebo.

Published
May 1, 2022
Journal
European Neuropsychopharmacology
Authors
Wießner, I., Olivieri, R., Falchi, M., Palhano-Fontes, F., Maia, L. O., Feilding, A., Araújo, D. B., Ribeiro, S., Tófoli, L.F.

Clinical Trials

0 trials

No clinical trials have been tagged with both LSD and Neurocognitive Disorders yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all LSD papers Search all Neurocognitive Disorders trials Full LSD profile Full Neurocognitive Disorders profile